Geospatial disparities in federal COVID-19 test-to-treat program ================================================================ * Emily R. Smith * Erin M. Oakley ## Abstract **Background** Paxlovid is authorized for the treatment of COVID-19 and must be used within the first 5 days of symptom onset. This limited window for initiating treatment makes rapid access critical. Federal Test-to-Treat programs provide tests, prescriptions, and medication in one visit3. **Objective** The objective of this study was to map the location of and identify disparities in access to Test-to-Treat programs in the United States (U.S.). **Methods** We obtained location data for public providers of Paxlovid and Test-to-Treat programs in the contiguous U.S. and examined their spatial distribution at the zip code tabulation area level. We defined zip codes as underserved if there was no Test-to-Treat program located within the zip code or within 20 miles of its boundaries. **Results** More than 52,000,000 people—representing 16% of the continental U.S. population—do not have access to a Test-to-Treat program in their zip code or within 20 miles. The majority of zip codes representing metropolitan areas have a Test-to-Treat program within 20 miles (77%). In contrast, only 30% of small towns and 23% of rural areas have nearby access. Zip codes with a high proportion of Hispanic and Black residents were likely to have access to nearby Test-to-Treat programs (72%, 70%). In contrast, zip codes with a high proportion of Native American residents were likely to be underserved (70%). About half of high-poverty zip codes do not have access to a Test-to-Treat program within 20 miles. **Discussion** Disparities in outcomes related to COVID-19 have been apparent since the beginning of the pandemic and continue to grow. While the multi-dimensional measure of social vulnerability was used to expand the federal Test-to-Treat program, some populations remain without access. ## Introduction Ritonavir-Boosted Nirmatrelvir (Paxlovid) is an antiviral drug indicated for the treatment of COVID-19 among non-hospitalized adults and children aged ≥12 years who are at high risk of disease progression. In the original trial, Paxlovid reduced the risk of hospitalization or death by 88% among high-risk, unvaccinated adults1. Paxlovid is authorized for use within the first 5 days of symptom onset2. This limited window for initiating treatment makes rapid access critical. In March 2022, the Biden-Harris administration established Test-to-Treat programs that provide tests, prescriptions, and medication in one visit3. Patients without access to Test-to-Treat programs are advised to contact their primary care provider (PCP) or visit a community health center. However, one in four Americans are without a PCP4. In May 2022, additional Test-to-Treat facilities were established to improve access in areas with high social vulnerability3. No studies have subsequently examined disparities in access to the program. The objective of this study was to map the location of and identify disparities in access to Test-to-Treat programs in the United States (U.S.). ## Methods We obtained location data for public providers of Paxlovid and Test-to-Treat programs in the contiguous U.S. from the Department of Health & Human Services on July 18, 2022. We examined their spatial distribution at the zip code tabulation area level. We defined zip codes as underserved if there was no Test-to-Treat program located within the zip code or within 20 miles of its boundaries. We obtained data on population, urbanicity, race and ethnicity, and poverty for each zip code (see supplemental methods material). ## Results We found an unequal geographic distribution of Test-to-Treat programs across the United States (Figure 1). More than 52,000,000 people living in 14,812 zip codes—representing 16% of the continental U.S. population—do not have access to a Test-to-Treat program in their zip code or within 20 miles. ![Figure 1.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/08/03/2022.08.02.22278349/F1.medium.gif) [Figure 1.](http://medrxiv.org/content/early/2022/08/03/2022.08.02.22278349/F1) Figure 1. Distribution of Test-to-Treat Centers and Public Therapeutic Providers stocking Paxlovid in the Continental United States, July 18, 2022 The majority of zip codes representing metropolitan areas have a Test-to-Treat program within 20 miles (77%). In contrast, only 30% of small towns and 23% of rural areas have nearby access (Table 1). Zip codes with a high proportion of Hispanic and Black residents were likely to have access to nearby Test-to-Treat programs (72%, 70%). In contrast, zip codes with a high proportion of Native American residents were likely to be underserved (70%). About half of high-poverty zip codes do not have access to a Test- to-Treat program within 20 miles. View this table: [Table 1.](http://medrxiv.org/content/early/2022/08/03/2022.08.02.22278349/T1) Table 1. Characteristics of Underserved Zip Codes (Compared to Served) in the Continental United States ## Discussion Disparities in outcomes related to COVID-19 have been apparent since the beginning of the pandemic and continue to grow. We found people living in more rural areas were much less likely to have access to nearby Test-to-Treat programs compared to metropolitan areas. This parallels trends in the cumulative COVID-19 death rate which is increasingly higher among people living in rural and micropolitan areas5. The Test-to-Treat program was specifically designed to reduce barriers to quickly accessing treatment, and indeed nearly half of all sites were located in high vulnerability zip codes by May 20226. However, we found that the majority zip codes with the highest proportion of American Indian and Alaska Native residents were underserved and that almost half of those with a high poverty rate remain underserved. While the multi-dimensional measure of social vulnerability was used to expand the federal Test-to-Treat program, some populations remain without access. Our findings have several limitations. First, we did not address whether underserved populations successfully access Paxlovid directly through PCPs and community pharmacies. Second, geographic access is only one aspect of ensuring treatment access; previous work found that Paxlovid was under-prescribed in high-vulnerability zip codes despite hosting a high proportion of Test-to-Treat programs6. In an effort to reduce barriers to antivirals, the FDA authorized state-licensed pharmacists to directly prescribe Paxlovid on July 6, 20227. While this is intended to expand treatment access, community pharmacies not participating in the Test-to-Treat program may not offer this service to patients. Public data is needed to understand whether this policy reduces disparities. Further, expanded access must be coupled with increased outreach to patients and providers6. Achieving pharmacoequity is an important goal, especially in the context of an ongoing pandemic with major disparities in health outcomes. Policy efforts, and transparent data, are key to addressing these disparities. ## Supporting information Supplemental Methods Material [[supplements/278349_file02.pdf]](pending:yes) ## Data Availability All data produced in the present study are available upon request to the authors * Received August 2, 2022. * Revision received August 2, 2022. * Accepted August 3, 2022. * © 2022, Posted by Cold Spring Harbor Laboratory This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/) ## References 1. 1.Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022;386(15):1397–1408. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/nejmoa2118542&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F08%2F03%2F2022.08.02.22278349.atom) 2. 2.National Institutes of Health. Ritonavir-Boosted Nirmatrelvir (Paxlovid). COVID-19 Treatment Guidelines. Published May 13, 2022. Accessed July 22, 2022. [https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ritonavir-boosted-nirmatrelvir--paxlovid-/](https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ritonavir-boosted-nirmatrelvir--paxlovid-/) 3. 3.Office of the Assistant Secretary for Preparedness & Response. Fact Sheet: Federally-Supported Test to Treat Sites. U.S. Department of Health and Human Services. Published May 2022. Accessed July 22, 2022. [https://aspr.hhs.gov/TestToTreat/Documents/ASPR-Fact-Sheet-Federally-Supported-Test-to-Treat-Sites.pdf](https://aspr.hhs.gov/TestToTreat/Documents/ASPR-Fact-Sheet-Federally-Supported-Test-to-Treat-Sites.pdf) 4. 4.Levine DM, Linder JA, Landon BE. Characteristics of Americans With Primary Care and Changes Over Time, 2002-2015. JAMA Intern Med. 2020;180(3):463–466. 5. 5.CDC. COVID Data Tracker. Centers for Disease Control and Prevention. Accessed July 22, 2022. [https://covid.cdc.gov/covid-data-tracker/#pop-factors\_7daynewdeaths](https://covid.cdc.gov/covid-data-tracker/#pop-factors_7daynewdeaths) 6. 6.Gold JAW, Kelleher J, Magid J, et al. Dispensing of Oral Antiviral Drugs for Treatment of COVID-19 by Zip Code-Level Social Vulnerability - United States, December 23, 2021-May 21, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(25):825–829. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.15585/mmwr.mm7125e1&link_type=DOI) 7. 7.Tanne JH. Covid-19: FDA authorises pharmacists to prescribe Paxlovid. BMJ. 2022;378:o1695. [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiRlVMTCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjE3OiIzNzgvanVsMDhfNy9vMTY5NSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIyLzA4LzAzLzIwMjIuMDguMDIuMjIyNzgzNDkuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9)